Vascular dysfunction and cardiovascular complications

Current Opinion in HIV and AIDS

Volumn 2, Issue 4, 2007, Pages 299-304

  Triant, Virginia A ^a   Grinspoon, Steven K ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cardiovascular; Endothelial dysfunction; HIV; Myocardial infarction

Indexed keywords

C REACTIVE PROTEIN; INDINAVIR; METFORMIN; PROTEINASE INHIBITOR; ROSIGLITAZONE;

ADVERSE OUTCOME; ARTERY DIAMETER; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CLINICAL TRIAL; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW;

EID: 34250644229     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3281e7e831     Document Type: Review

References (53)

1. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults [see comment]. N Engl J Med 2005; 352:48-62.
2. Paton P, Tabib A, Loire R, Tete R. Coronary artery lesions and human immunodeficiency virus infection. Res Virol 1993; 144:225-231.
3. Tabib A, Leroux C, Mornex JF, Loire R. Accelerated coronary atherosclerosis and arteriosclerosis in young human-immunodeficiency-virus- positive patients. Coron Artery Dis 2000; 11:41-46.
4. Best P, Edwards W, Holmes D, Lerman A. Unique coronary arteriopathy associated with human immunodeficiency virus. J Am Coll Cardiol 1998; 31 (Suppl 1):272.
5. Zhou H, Pandak WM Jr, Lyall V, et al. HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease. Mol Pharmacol 2005; 68:690-700.
6. Baliga RS, Chaves AA, Jing L, et al. AIDS-related vasculopathy: evidence for oxidative and inflammatory pathways in murine and human AIDS. Am J Physiol Heart Circ Physiol 2005; 289:H1373-H1380.
7. Shankar SS, Dube MP, Gorski JC, et al. Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J 2005; 150:933.
8. Schillaci G, De Socio GV, Pirro M, et al. Impact of treatment with protease inhibitors on aortic stiffness in adult patients with human immunodeficiency virus infection [see comment]. Arterioscler Thromb Vasc Biol 2005; 25:2381-2385.
9. Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109:1603-1608.
10. Chironi G, Escaut L, Gariepy J, et al. Brief report: carotid intima-media thickness in heavily pretreated HIV-infected patients. J Acquir Immune Defic Syndr 2003; 32:490-3 [erratum appears in J Acquir Immune Defic Syndr. 2003; 33:180].
11. Currier J, Kendall M, Henry K, et al. 3-year follow-up of carotid intima-media thickness in HIV-infected and uninfected adults: ACTG 5078. In: 13th Conference on Retroviruses and Opportunistic Infections. Denver, Colorado, USA, 5-8 February 2006. Abstract 735.
12. Hsue PY, Hunt PW, Sinclair E, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS 2006; 20:2275-2283. This novel study investigates the relationship between IMT, CRP and CMV-specific T-cell responses.
13. Currier JS, Kendall MA, Zackin R, et al. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure [see comment]. AIDS 2005; 19:927-933.
14. Johnsen S, Dolan SE, Fitch KV, et al. Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome. J Clin Endocrinol Metab 2006; 91:4916-4924.
15. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104:257-262.
16. Solages A, Vita JA, Thornton DJ, et al. Endothelial function in HIV-infected persons [see comment]. Clin Infect Dis 2006; 42:1325-1332.
17. Blum A, Hadas V, Burke M, et al. Viral load of the human immunodeficiency virus could be an independent risk factor for endothelial dysfunction. Clin Cardiol 2005; 28:149-153.
18. Hurlimann D, Chenevard R, Ruschitzka F, et al. Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing antiretroviral combination therapy: a randomised double blind crossover trial. Heart 2006; 92:110-112. This is one of the first studies to examine a potential intervention for vascular disease in HIV patients by assessing the effect of pravastatin on plasma lipid profiles and endothelial dysfunction as measured by flow-mediated vasodilatation.
19. van Wijk JP, de Koning EJ, Cabezas MC, et al. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. Ann Intern Med 2005; 143:337-46 [erratum appears in Ann Intern Med 2005; 143:695 Note: dosage error in text]
20. [summary for patients in Ann Intern Med 2005; 143:138].
21. Depairon M, Chessex S, Sudre P, et al. Premature atherosclerosis in HIV-infected individuals-focus on protease inhibitor therapy. AIDS 2001; 15:329-334.
22. Maggi P, Serio G, Epifani G, et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 2000; 14:F123-F128.
23. Thompson GR, Partridge J. Coronary calcification score: the coronary-risk impact factor. Lancet 2004; 363:557-559.
24. Talwani R, Falusi OM, Mendes de Leon CF, et al. Electron beam computed tomography for assessment of coronary artery disease in HIV-infected men receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 30:191-195.
25. Acevedo M, Sprecher DL, Calabrese L, et al. Pilot study of coronary atherosclerotic risk and plaque burden in HIV patients: 'a call for cardiovascular prevention'. Atherosclerosis 2002; 163:349-354.
26. Meng Q, Lima JA, Lai H, et al. Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors. Am Heart J 2002; 144:642-648.
27. Mangili A, Gerrior J, Tang AM, et al. Risk of cardiovascular disease in a cohort of HIV-infected adults: a study using carotid intima-media thickness and coronary artery calcium score. Clin Infect Dis 2006; 43:1482-1489. Coronary artery calcification scores are examined in HIV patients with respect to gender.
28. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and lowdensity lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347:1557-1565.
29. Dolan SE, Hadigan C, Killilea KM, et al. Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr 2005; 39:44-54.
30. Saves M, Chene G, Ducimetiere P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003; 37:292-298.
31. Sattler FR, Qian D, Louie S, et al. Elevated blood pressure in subjects with lipodystrophy. AIDS 2001; 15:2001-2010.
32. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17:1179-1193.
33. Mamary EM, Bahrs D, Martinez S. Cigarette smoking and the desire to quit among individuals living with HIV. AIDS Patient Care STDS 2002; 16:39-42.
34. Gritz ER, Vidrine DJ, Lazev AB, et al. Smoking behavior in a low-income multiethnic HIV/AIDS population. Nicotine Tob Res 2004; 6:71-77.
35. Vittecoq D, Escaut L, Chironi G, et al. Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatmentera. AIDS 2003; 17(Suppl 1):S70-S76.
36. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33:506-512.
37. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30:471-477.
38. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction [see comment]. N Engl J Med 2003; 349:1993-2003 [erratum appears in N Engl J Med 2004; 350:955].
39. Mary-Krause M, Cotte L, Simon A, et al. Clinical Epidemiology Group from the French Hospital D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men [see comment]. AIDS 2003; 17:2479-2486.
40. Holmberg S. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360:1747-1748.
41. Iloeje UH, Yuan Y, L'Italien G, et al. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med 2005; 6:37-44.
42. Bozzette SA, Ake CF, Tam HK, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection [see comment]. N Engl J Med 2003; 348:702-710.
43. Coplan PM, Nikas AA, Leavitt RY, et al. Indinavir did not increase the shortterm risk of adverse cardiovascular events relative to nucleoside reverse transcriptase inhibitor therapy in four phase III clinical trials [see comment]. AIDS 2001; 15:1584-1586.
44. Klein D, Hurley L, Quesenberry C, et al. Hospitalizations for CHD and MI among northern California HIV+ and HIV- men: changes in practice and Framingham Risk Scores. In: 13th Conference on Retroviruses and Opportunistic Infections. Denver, Colorado, USA, 5-8 February 2006. Abstract 737.
45. Klein D, Hurley L, Silverberg M, et al. Surveillance data for myocardial infarction hospitalizations among HIV+ and HIV- northern Californians: 1994-2006. In: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, California, USA, 25-28 February 2007. Abstract 807. Updated data are presented from the ongoing study of CHD and AMI rates in HIV patients compared with controls in the northern California Kaiser Permanente HMO.
46. Triant VA, Lee H, Hadigan C, Grinspoon S. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with HIV disease (in press). J Clin Endocrinol Metab 2007.
47. Friis-Moller N, Reiss P, El-Sadr W, et al. Exposure to PI and NNRTI and risk of myocardial infarction: results from the D:A:D Study. In: 13th Conference on Retroviruses and Opportunistic Infections. Denver, Colorado, USA, 5-8 February 2006. Abstract 144. The DAD cohort is the largest prospectively followed HIV cohort and presents updated data on the relative risk of AMI with increasing duration of ARV exposure.
48. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296. The SMART study compares continuous ARV treatment with structured interruption with respect to treatment outcomes and side-effects and specifically examined cardiovascular effects.
49. Escaut L, Monsuez JJ, Chironi G, et al. Coronary artery disease in HIV infected patients. Intensive Care Med 2003; 29:969-973.
50. Boccara F, Ederhy S, Janower S, et al. Clinical characteristics and mid-term prognosis of acute coronary syndrome in HIV-infected patients on antiretroviral therapy. HIV Med 2005; 6:240-244.
51. Hsue PY, Giri K, Erickson S, et al. Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation 2004; 109:316-319.
52. Matetzky S, Domingo M, Kar S, et al. Acute myocardial infarction in human immunodeficiency virus-infected patients. Arch Intern Med 2003; 163:457-460.
53. Boccara F, Teiger E, Cohen A, et al. Percutaneous coronary intervention in HIV infected patients: immediate results and long term prognosis. Heart 2006; 92:543-544.